These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 17372930)

  • 1. Reversal of BCRP-mediated multidrug resistance by stable expression of small interfering RNAs.
    Lv H; He Z; Liu X; Yuan J; Yu Y; Chen Z
    J Cell Biochem; 2007 Sep; 102(1):75-81. PubMed ID: 17372930
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Co-expression of cytokeratin 8 and breast cancer resistant protein indicates a multifactorial drug-resistant phenotype in human breast cancer cell line.
    Liu F; Fan D; Qi J; Zhu H; Zhou Y; Yang C; Zhu Z; Xiong D
    Life Sci; 2008 Sep; 83(13-14):496-501. PubMed ID: 18725232
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modulation of BCRP mediated atypical multidrug resistance phenotype by RNA interference.
    Li WT; Zhou GY; Song XR; Chi WL; Ren RM; Wang XW
    Neoplasma; 2005; 52(3):219-24. PubMed ID: 15875083
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Suppression of BCRP expression and restoration of sensitivity to chemotherapy in multidrug-resistant HCC cell line HEPG2/ADM by RNA interference.
    Li H; Zhou S; Li T; Liu Z; Wu J; Zeng G; Liu C; Gong J
    Hepatogastroenterology; 2012 Oct; 59(119):2238-42. PubMed ID: 23435138
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transcriptional modulation of BCRP gene to reverse multidrug resistance by toremifene in breast adenocarcinoma cells.
    Zhang Y; Wang H; Wei L; Li G; Yu J; Gao Y; Gao P; Zhang X; Wei F; Yin D; Zhou G
    Breast Cancer Res Treat; 2010 Oct; 123(3):679-89. PubMed ID: 19967559
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Regulation mechanism of breast cancer resistance protein by toremifene to reverse BCRP-mediated multidrug resistance in breast cancer cells].
    Zhang YH; Li G; Yu J; Xu MS; Liu ZX
    Zhonghua Zhong Liu Za Zhi; 2011 Sep; 33(9):654-60. PubMed ID: 22340044
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Complete reversal of ABCG2-depending atypical multidrug resistance by RNA interference in human carcinoma cells.
    Priebsch A; Rompe F; Tönnies H; Kowalski P; Surowiak P; Stege A; Materna V; Lage H
    Oligonucleotides; 2006; 16(3):263-74. PubMed ID: 16978089
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modulation of the atypical multidrug-resistant phenotype by a hammerhead ribozyme directed against the ABC transporter BCRP/MXR/ABCG2.
    Kowalski P; Stein U; Scheffer GL; Lage H
    Cancer Gene Ther; 2002 Jul; 9(7):579-86. PubMed ID: 12082458
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reversal of breast cancer resistance protein (BCRP/ABCG2)-mediated drug resistance by novobiocin, a coumermycin antibiotic.
    Shiozawa K; Oka M; Soda H; Yoshikawa M; Ikegami Y; Tsurutani J; Nakatomi K; Nakamura Y; Doi S; Kitazaki T; Mizuta Y; Murase K; Yoshida H; Ross DD; Kohno S
    Int J Cancer; 2004 Jan; 108(1):146-51. PubMed ID: 14618629
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Selection and characterization of a high-activity ribozyme directed against the antineoplastic drug resistance-associated ABC transporter BCRP/MXR/ABCG2.
    Kowalski P; Wichert A; Holm PS; Dietel M; Lage H
    Cancer Gene Ther; 2001 Mar; 8(3):185-92. PubMed ID: 11332989
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro and in vivo evaluation of WK-X-34, a novel inhibitor of P-glycoprotein and BCRP, using radio imaging techniques.
    Jekerle V; Klinkhammer W; Scollard DA; Breitbach K; Reilly RM; Piquette-Miller M; Wiese M
    Int J Cancer; 2006 Jul; 119(2):414-22. PubMed ID: 16646006
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2).
    Doyle L; Ross DD
    Oncogene; 2003 Oct; 22(47):7340-58. PubMed ID: 14576842
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Developing multidrug-resistant cells and exploring correlation between BCRP/ABCG2 over-expression and DNA methyltransferase.
    Ji N; Yuan J; Liu J; Tian S
    Acta Biochim Biophys Sin (Shanghai); 2010 Dec; 42(12):854-62. PubMed ID: 21106767
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mitochondrial expression and functional activity of breast cancer resistance protein in different multiple drug-resistant cell lines.
    Solazzo M; Fantappiè O; D'Amico M; Sassoli C; Tani A; Cipriani G; Bogani C; Formigli L; Mazzanti R
    Cancer Res; 2009 Sep; 69(18):7235-42. PubMed ID: 19706772
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modulation of breast cancer resistance protein (BCRP/ABCG2) gene expression using RNA interference.
    Ee PL; He X; Ross DD; Beck WT
    Mol Cancer Ther; 2004 Dec; 3(12):1577-83. PubMed ID: 15634651
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transcriptional targeting of human liver carboxylesterase (hCE1m6) and simultaneous expression of anti-BCRP shRNA enhances sensitivity of breast cancer cells to CPT-11.
    Mishra MN; Vangara KK; Palakurthi S
    Anticancer Res; 2014 Nov; 34(11):6345-51. PubMed ID: 25368234
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gefitinib ("Iressa", ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor, reverses breast cancer resistance protein/ABCG2-mediated drug resistance.
    Nakamura Y; Oka M; Soda H; Shiozawa K; Yoshikawa M; Itoh A; Ikegami Y; Tsurutani J; Nakatomi K; Kitazaki T; Doi S; Yoshida H; Kohno S
    Cancer Res; 2005 Feb; 65(4):1541-6. PubMed ID: 15735043
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sensitization of ABCG2-overexpressing cells to conventional chemotherapeutic agent by sunitinib was associated with inhibiting the function of ABCG2.
    Dai CL; Liang YJ; Wang YS; Tiwari AK; Yan YY; Wang F; Chen ZS; Tong XZ; Fu LW
    Cancer Lett; 2009 Jun; 279(1):74-83. PubMed ID: 19232821
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MiR-181a enhances drug sensitivity in mitoxantone-resistant breast cancer cells by targeting breast cancer resistance protein (BCRP/ABCG2).
    Jiao X; Zhao L; Ma M; Bai X; He M; Yan Y; Wang Y; Chen Q; Zhao X; Zhou M; Cui Z; Zheng Z; Wang E; Wei M
    Breast Cancer Res Treat; 2013 Jun; 139(3):717-30. PubMed ID: 23780685
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MiR-487a resensitizes mitoxantrone (MX)-resistant breast cancer cells (MCF-7/MX) to MX by targeting breast cancer resistance protein (BCRP/ABCG2).
    Ma MT; He M; Wang Y; Jiao XY; Zhao L; Bai XF; Yu ZJ; Wu HZ; Sun ML; Song ZG; Wei MJ
    Cancer Lett; 2013 Oct; 339(1):107-15. PubMed ID: 23879965
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.